anti-PD-1
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
... that PD-1/PD-L1 is a promising target to reverse the immune evasion of gli- oma ...measured PD-L1 expression in 94 patients and found that PD-L1 was a negative prognostic indicator for ...
13
Mitochondria Determine Response to Anti-PD-1 Therapy: An Evidence-based Hypothesis
... death 1 (PD-1) axis are the most encouraging field of research in this context (4, ...of Anti–PD(L)-1 therapy is about 20% for unknown reasons ...from ...
9
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
... of anti–PD-1 mAb from NPs. To study the release of anti–PD-1 mAb from NPs, the NPs were loaded onto the filter in an ultrafiltration centrifuge tube, and the bottom of the tube ...
18
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
... of anti-PD-1 and CXCR4 targeting on human cancer cells PES43 human melanoma [25] xenograft was ...express PD-1 (61,3%); low level of PD-L1 ...human ...
13
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
... recent anti-PD-1 biomarker study, high relative lymphocyte counts ...in anti-CTLA-4 treated melanoma patients ...the anti-CTLA-4 or anti-PD-1 cohorts (Additional ...
14
Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes
... of anti–PD-1 therapy on ...by anti–PD-1 therapy that are critical for conferring effective antitumor immune ...to anti–PD-1 therapy, to shape antitumor ...
16
Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
... therapy. Anti-PD-1 Abs have emerged as powerful ...following anti-PD1 Ab therapy in patients with non-small-cell lung cancer (NSLC), accompanied by extended overall ...
5
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
... of anti – PD-1/anti – CTLA-4 therapy for BrM, we compared therapeutic efficacy between mice bearing intracranial tumors only [representing a conventional intracranial tumor trans- plantation ...
10
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... Our findings also showed that patients with EGFR wild-type NSCLC derived better OS improvement with anti-PD-1/anti-PD-L1 than tumours harbouring common EGFR mutations. Of note, the ...
11
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
... both anti-PD-1 and anti-CTLA-4 ...(prednisone 1–2 mg/kg/day or ...h), anti-thymocyte globulin therapy have been reported as well ...
8
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
... Paraneoplastic syndromes (PNSs) are rare autoimmune disorders associated with cancer [7, 8]. The complex pathogenesis of these syndromes is mediated by either sol- uble factors (such as hormones or cytokines secreted by ...
12
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
... death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration resistant prostate cancer (mCRPC) showed no evidence of ...
8
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
... between PD-1 and KIR. We observed KIR expression before and after anti-PD-1 monoclonal antibody ...to anti-PD-1 monoclonal anti- body treatment might be ...
6
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
... with anti- PD-1/PD-L1 antibody ...and anti-PD-L1 antibody and some other subgroups, but high heterogeneity was still found in most part of ...of anti-PD1/PD-L1 ...
12
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
... of PD-1 positive (+) TILs in cancer ...of PD-1(+) TILs were significantly associated with prolonged disease-free survival of pulmonary squamous cell carcinoma (SqCC) patients ...of ...
12
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
... ≥ 15 mut/Mb in NSCLC patients treated with nivolumab plus ipilimumab as a first-line therapy. Subsequently, TMB ≥ 10 mut/Mb was regarded as the criteria to differ- entiate the high TMB and low TMB cohorts in the Check- ...
14
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
... The present study is the first to our knowledge to demonstrate the predictive value of CTLA4 meth- ylation in a treatment cohort of melanoma patients with long-term follow-up in response to immune checkpoint inhibition. ...
10
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
... gational anti-PD-1) without concurrent use of metfor- min (cohort A), or with concurrent use of metformin (cohort ...least 1 week were included in cohort ...than 1 week were excluded ...
10
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
... express PD-L1 and he received off-label pembrolizumab 2 mg/kg every 21 days for 13 cycles with marked shrinkage of his liver disease and no new facial ...express PD-L1 and have a sustained response to ...
5
Anti–PD 1/PD L1 therapy of human cancer: past, present, and future
... tumor-associated PD-L1 facilitates apoptosis of activated T cells (17) and also stimulates IL-10 pro- duction in human peripheral blood T cells (4) to mediate immune ...of PD-L1 on immune suppression are ...
9